Medpace Holdings, Inc. (MEDP) Stock Price: $461.60-5.90 (-1.26%)
At close: Jun 16, 2026, 4:00 PM ET
The closing share price for Medpace Holdings, Inc. (MEDP) stock was $461.60 for Tuesday, June 16, 2026, down 1.26% on the day.
Longer view (total return, dividends reinvested): past 12 months +53.4% · 3-year avg +27.7%/yr · 5-year avg +20.9%/yr
MEDP Price Chart
MEDP is featured in
MEDP Key Metrics
See All MetricsLAST CLOSE PRICE
$461.60
52-WEEK RANGE
$294.07 - $628.92
BETA
1.18
% FROM 52W HIGH
-26.60%
MARKET CAP
$13.18B
DIVIDEND YIELD
N/A
PE RATIO
trailing TTM
28.99
PE RATIO (FWD)
next-FY estimate
25.12
P/B RATIO
22.34
DEBT / EQUITY
0.55
REVENUE TTM
$2.68B
NET INCOME TTM
$460.40M
NET PROFIT MARGIN TTM
17.19%
TTM TOTAL RETURN
+53.41%
3Y TOTAL RETURN
+27.66%
5Y TOTAL RETURN
+20.87%
MEDP Earnings Preview
Next Earnings Date
Jul 20, 2026
33 days away
EPS Estimate
3.98
Revenue Est.
$690.69M
Last Quarter Results
EPS
$4.28
vs Estimate
$3.96
Revenue
$706.60M
vs Estimate
$697.60M
MEDP Analyst Ratings
Consensus Rating
Based on 12 analysts
Average Price Target
$442.83
-4.1% downside
Low
$329.00
Current
$461.60
High
$495.00
MEDP Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2028 | $5.25 | $5.38 | $5.55 | 2 |
| Q2 2028 | $5.18 | $5.31 | $5.47 | 2 |
| Q3 2028 | $5.41 | $5.55 | $5.72 | 2 |
| Q4 2028 | $5.74 | $5.89 | $6.07 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $17.24 | $18.37 | $19.09 | 9 |
| FY 2028 | $19.13 | $20.84 | $24.50 | 9 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2028 | $771.67M | $786.49M | $805.40M | 2 |
| Q2 2028 | $792.78M | $808.00M | $827.43M | 2 |
| Q3 2028 | $824.30M | $840.13M | $860.33M | 2 |
| Q4 2028 | $852.85M | $869.23M | $890.13M | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $2.71B | $2.91B | $3.17B | 9 |
| FY 2028 | $3.14B | $3.16B | $3.18B | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareMEDP Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MEDP | $13.18B | $461.60 | -1.26% | +53.41% | +20.87% | N/A | — |
| 2COO | $13.14B | $67.35 | -0.61% | -3.43% | -6.72% | +5.18% | vs MEDP |
| 3SOLV | $13.26B | $76.56 | -0.44% | +2.84% | N/A | N/A | vs MEDP |
| 4DVA | $13.46B | $208.98 | -0.37% | +53.59% | +11.14% | +10.81% | vs MEDP |
| 5ALGN | $12.86B | $179.52 | +0.71% | -1.64% | -21.43% | +8.51% | vs MEDP |
| 6RVTY | $11.29B | $101.22 | +0.67% | +5.36% | -7.20% | +7.05% | vs MEDP |
MEDP Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle